keyword
MENU ▼
Read by QxMD icon Read
search

pharmacoeconomic

keyword
https://www.readbyqxmd.com/read/29455643/chronic-myeloid-leukemia-the-paradigm-of-targeting-oncogenic-tyrosine-kinase-signaling-and-counteracting-resistance-for-successful-cancer-therapy
#1
REVIEW
Simona Soverini, Manuela Mancini, Luana Bavaro, Michele Cavo, Giovanni Martinelli
Deregulated activity of BCR-ABL1, a nonreceptor tyrosine kinase encoded by the fusion gene resulting from the t(9;22)(q34;q11) chromosomal translocation, is thought to be the driver event responsible for initiation and maintenance of chronic myeloid leukemia (CML). BCR-ABL1 was one of the first tyrosine kinases to be implicated in a human malignancy and the first to be successfully targeted. Imatinib mesylate, the first tyrosine kinase inhibitor (TKI) to be approved for therapeutic use, was hailed as a magic bullet against cancer and remains one of the safest and most effective anticancer agents ever developed...
February 19, 2018: Molecular Cancer
https://www.readbyqxmd.com/read/29442526/cost-efficacy-analysis-of-3-diclofenac-sodium-ingenol-mebutate-and-3-75-imiquimod-in-the-treatment-of-actinic-keratosis
#2
Steven Nisticò, Ester Del Duca, Valeria Torchia, Micaela Gliozzi, Ugo Bottoni, Carolina Muscoli
Actinic keratosis (AK) is a clinical condition characterized by keratinocytic dysplastic lesions of the epidermis, affecting individuals chronically exposed to sunlight. Topical therapies allow the treatment of a whole area of affected skin and currently include diclofenac sodium gel, 5-fluorouracil cream, 5-fluorouracil and acetylsalicylic acid solution, imiquimod cream, and ingenol mebutate gel. Due to the comparable efficacy of 3% diclofenac, ingenol mebutate, and 3.75% imiquimod in treating AK multiple lesions, a pharmacoeconomic evaluation of cost-effectiveness of the three treatments was needed...
January 2018: International Journal of Immunopathology and Pharmacology
https://www.readbyqxmd.com/read/29433132/-the-economic-value-of-vaccinations-a-systematic-review-of-italian-economic-evaluations-and-hta-reports
#3
Francesco Di Nardo, Sara Boccalini, Giovanna Elisa Calabrò, Andrea Marcellusi, Matteo Ruggeri, Paolo Bonanni, Raffaella Vitali, Eleonora Capannini, Francesco Saverio Mennini, Americo Cicchetti, Donatella Panatto, Roberto Gasparini, Walter Ricciardi, Chiara De Waure
INTRODUCTION: Decision-making in healthcare should rely on evidence-based approaches able to make possible a transparent and robust assessment of all the aspects related to health technologies. One of the assessment elements is represented by the efficiency that is the specific objective of economic evaluations and also of Health Technology Assessment (HTA). The collection and synthesis of evidence is the first indispensable step in order to foster a proper convey of scientific knowledge to the decision-makers...
September 2017: Igiene e Sanità Pubblica
https://www.readbyqxmd.com/read/29430411/comparison-of-efficacy-and-pharmacoeconomics-of-two-helicobacter-pylori-eradication-regimens-in-peptic-ulcer-disease
#4
Syeda Zaineb Kubra Hussaini, Syeda Zaineb Humaira Hussaini, Ruheena Yasmeen, Bader Unnisa, Aamir Ali Asgar Syed, Md Nematullah Khan, Syed Ibrahim Hassan
Background: Helicobacter pylori , the cause of most peptic ulcer diseases, infects approximately 50% of the population worldwide. Indian data on cost and effectiveness of the standard first-line therapies for H. pylori eradication are scarce. Thus, the present study was aimed at comparing the cost and efficacy of two standard first-line therapies: Regimen I comprising pantoprazole (40 mg) plus amoxicillin (750 mg) plus clarithromycin (500 mg) (PAC) and Regimen II comprising rabeprazole (20 mg) plus amoxicillin (625 mg) plus metronidazole (200 mg) (RAM)...
January 2018: Perspectives in Clinical Research
https://www.readbyqxmd.com/read/29408775/value-based-procurement-of-medical-devices-application-to-devices-for-mechanical-thrombectomy-in-ischemic-stroke
#5
Sabrina Trippoli, Erminia Caccese, Claudio Marinai, Andrea Messori
OBJECTIVES: In the acute ischemic stroke, endovascular devices have shown promising clinical results and are also likely to represent value for money, as several modeling studies have shown. Pharmacoeconomic evaluations in this field, however, have little impact on the procurement of these devices. The present study explored how complex pharmacoeconomic models that evaluate effectiveness and cost can be incorporated into the in-hospital procurement of thrombectomy devices. PATIENTS AND METHODS: As regards clinical modeling, we extracted outcomes at three months from randomized trials conducted for four thrombectomy devices, and we projected long-term results using standard Markov modeling...
January 29, 2018: Clinical Neurology and Neurosurgery
https://www.readbyqxmd.com/read/29408752/ulipristal-acetate-for-pre-operative-management-of-uterine-fibroids-modeling-outcomes-and-costs
#6
Brigitta Badiani, Marco Chiumente, Andrea Messori
OBJECTIVES: The aim of this study was to evaluate the pharmacoeconomic profile in Italy of preoperative treatment with ulipristal acetate at the dose of 5 mg/day for 13 weeks in comparison with placebo prior to surgical management of symptomatic uterine fibroids. STUDY DESIGN: The pharmacoeconomic analysis was based on the calculation of incremental cost-effectiveness ratio (ICER). Effectiveness data were derived from the randomized-controlled trial PEARL-1, whilst costs data were retrieved from the published literature...
February 1, 2018: European Journal of Obstetrics, Gynecology, and Reproductive Biology
https://www.readbyqxmd.com/read/29406838/real-world-characteristics-and-treatment-patterns-in-patients-with-urticaria-initiating-omalizumab-in-the-united-states
#7
Xuehua Ke, Abhishek Kavati, Debra Wertz, Qing Huang, Liya Wang, Vincent J Willey, Judith J Stephenson, Benjamin Ortiz, Brandee Paknis, Jonathan A Bernstein, Lisa A Beck
BACKGROUND: Omalizumab is indicated for the management of chronic idiopathic urticaria (CIU) in patients aged 12 years or older with persistent hives that are not adequately controlled by H1 antihistamines. While its safety and efficacy in CIU patients have been evaluated in multiple clinical trials, real-world use of omalizaumab in CIU has not been well characterized. OBJECTIVE: To assess demographics, clinical characteristics, and treatment patterns of CIU patients who initiated omalizumab to better understand the usage of this agent in CIU management in the real world...
December 19, 2017: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29402243/treatment-decisions-clinical-outcomes-and-pharmacoeconomics-in-the-treatment-of-patients-with-egfr-mutated-stage-iii-iv-nsclc-in-germany-an-observational-study
#8
Wolfgang Schuette, Peter Schirmacher, Wilfried E E Eberhardt, Manfred Dietel, Ute Zirrgiebel, Lars Muehlenhoff, Michael Thomas
BACKGROUND: We evaluated treatment decisions and outcomes in a cohort of predominately Caucasian patients with EGFR mutation-positive (EGFR Mut+) non-small-cell lung cancer (NSCLC). METHODS: REASON (NCT00997230) was a non-interventional study in German patients with stage IIIB/IV NSCLC. Secondary endpoints for EGFR Mut + NSCLC included progression-free survival (PFS), overall survival (OS), adverse event (AE) management, and pharmacoeconomic outcomes. RESULTS: Among 334 patients with EGFR Mut + NSCLC, tyrosine kinase inhibitors (TKIs) were the most common first-line therapy (56...
February 5, 2018: BMC Cancer
https://www.readbyqxmd.com/read/29392230/pharmacoeconomics-of-genotyping-based-treatment-decisions-in-patients-with-chronic-pain
#9
Robert Morlock, Glenn D Braunstein
Introduction: Genotyping-based treatment decisions may optimize treatment response and minimize adverse drug events (ADEs) in patients with chronic pain. Objectives: To estimate the financial impact of genotyping-based treatment decisions in patients with moderate to severe chronic pain in a managed care setting. Methods: A budget impact model was built with a 1-year time horizon to estimate costs of genotyping-based treatment decisions in a 1000-patient cohort...
September 2017: Pain Reports (Baltimore, Md.)
https://www.readbyqxmd.com/read/29386902/update-on-subcutaneous-methotrexate-for-inflammatory-arthritis-and-psoriasis
#10
REVIEW
Gino Antonio Vena, Nicoletta Cassano, Florenzo Iannone
Methotrexate (MTX) is one of the mainstays of treatment for several immune-mediated inflammatory joint and skin diseases, especially rheumatoid arthritis (RA) and moderate-to-severe psoriasis. Oral MTX has been used for the treatment of such diseases for decades for many reasons. There is, however, a relevant interpatient variability of clinical and safety outcomes that can also be related to differences in patients' individual pharmacogenomic profile. Orally administered MTX has been found to have a saturable intestinal absorption and nonlinear pharmacokinetics, with significant consequences on drug bioavailability and clinical efficacy...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29378461/bringing-the-patient-back-in-behavioral-decision-making-and-choice-in-medical-economics
#11
Roger Lee Mendoza
We explore the behavioral methodology and "revolution" in economics through the lens of medical economics. We address two questions: (1) Are mainstream economic assumptions of utility-maximization realistic approximations of people's actual behavior? (2) Do people maximize subjective expected utility, particularly in choosing from among the available options? In doing so, we illustrate-in terms of a hypothetical experimental sample of patients with dry eye diagnosis-why and how utility in pharmacoeconomic assessments might be valued differently by patients when subjective psychological, social, cognitive, and emotional factors are considered...
February 16, 2018: Journal of Medical Economics
https://www.readbyqxmd.com/read/29371476/prospective-evaluation-of-the-impact-of-the-21-gene-recurrence-score-assay-on-adjuvant-treatment-decisions-for-women-with-node-positive-breast-cancer-in-ontario-canada
#12
Sofia Torres, Maureen Trudeau, Sonal Gandhi, Ellen Warner, Sunil Verma, Kathleen I Pritchard, Teresa Petrella, Mark Hew-Shue, Calvin Chao, Andrea Eisen
BACKGROUND: The 21-gene Recurrence Score (RS) assay is only reimbursed in Ontario for node-negative and micrometastatic node-positive (N+) early-stage breast cancer (EBC). We carried out a prospective study to evaluate the impact of the assay on treatment decisions for women with N+ EBC. Subjects, Materials, and Methods. Women with estrogen receptor-positive, human epidermal growth receptor 2-negative EBC and one to three positive axillary lymph nodes, who were candidates for adjuvant chemotherapy in addition to hormonal treatment, but in whom the benefit of chemotherapy was uncertain, were eligible...
January 25, 2018: Oncologist
https://www.readbyqxmd.com/read/29363389/real-world-analysis-of-dispensed-ius-of-coagulation-factor-ix-and-resultant-expenditures-in-hemophilia-b-patients-receiving-standard-half-life-versus-extended-half-life-products-and-those-switching-from-standard-half-life-to-extended-half-life-products
#13
Bartholomew J Tortella, José Alvir, Margaret McDonald, Dean Spurden, Patrick F Fogarty, Amit Chhabra, Andreas M Pleil
BACKGROUND: Hemophilia B requires replacement therapy with factor IX (FIX) coagulation products to treat and prevent bleeding episodes. A recently introduced extended half-life (EHL) recombinant FIX replacement product provided the opportunity to compare the amount of dispensed factor and expenditures for EHL treatment compared with a standard half-life (SHL) product. OBJECTIVE: To determine factor international units (IUs) dispensed and expenditures associated with switching from nonacog alfa, the most commonly used SHL replacement product, to eftrenonacog alfa, an EHL FIX replacement product...
January 24, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29352843/tocilizumab-after-a-first-line-with-anti-tnf-in-rheumatoid-arthritis-a-cost-consequence-analysis-in-the-italian-setting
#14
Sergio Iannazzo, Maurizio Benucci, Ennio Giulio Favalli
OBJECTIVES: Switching to a different mechanism of action in rheumatoid arthritis (RA) patients after a first anti-TNF-α has proved to be effective. The objective of this study was a health economic assessment in Italy. METHODS: The study was conducted using a pharmacoeconomic model with a 3-year time horizon. Effectiveness was measured as days gained in low disease activity (LDA; DAS28-ESR <3.2) or in remission (DAS28-ESR <2.6). The model simulated the response to treatments, based on the Rotation Or Change (ROC) trial, the probability of discontinuation and switch to a 3rd-line biologic, and the transition to death...
January 15, 2018: Clinical and Experimental Rheumatology
https://www.readbyqxmd.com/read/29330217/a-systematic-review-of-network-meta-analyses-for-pharmacological-treatment-of-common-mental-disorders
#15
REVIEW
Taryn Williams, Dan J Stein, Jonathan Ipser
QUESTION: Network meta-analyses (NMAs) of treatment efficacy across different pharmacological treatments help inform clinical decision-making, but their methodological quality may vary a lot depending also on the quality of the included primary studies. We therefore conducted a systematic review of NMAs of pharmacological treatment for common mental disorders in order to assess the methodological quality of these NMAs, and to relate study characteristics to the rankings of efficacy and tolerability...
February 2018: Evidence-based Mental Health
https://www.readbyqxmd.com/read/29313265/a-systematic-review-of-discrete-choice-experiments-and-conjoint-analysis-studies-in-people-with-multiple-sclerosis
#16
REVIEW
Edward J D Webb, David Meads, Ieva Eskyte, Natalie King, Naila Dracup, Jeremy Chataway, Helen L Ford, Joachim Marti, Sue H Pavitt, Klaus Schmierer, Ana Manzano
BACKGROUND: Multiple sclerosis (MS) is a chronic disabling, inflammatory, and degenerative disease of the central nervous system that, in most cases, requires long-term disease-modifying treatment (DMT). The drugs used vary in efficacy and adverse effect profiles. Several studies have used attribute-based stated-preference methods, primarily to investigate patient preferences for initiating or escalating DMT. OBJECTIVES: To conduct a systematic review of attribute-based stated-preference studies in people with MS to identify common methods employed and to assess study quality, with reference to the specific challenges of this disease area...
January 8, 2018: Patient
https://www.readbyqxmd.com/read/29310963/guidance-on-noncorticosteroid-systemic-immunomodulatory-therapy-in-noninfectious-uveitis-fundamentals-of-care-for-uveitis-focus-initiative
#17
REVIEW
Andrew D Dick, James T Rosenbaum, Hassan A Al-Dhibi, Rubens Belfort, Antoine P Brézin, Soon Phaik Chee, Janet L Davis, Athimalaipet V Ramanan, Koh-Hei Sonoda, Ester Carreño, Heloisa Nascimento, Sawsen Salah, Sherveen Salek, Jay Siak, Laura Steeples
TOPIC: An international, expert-led consensus initiative to develop systematic, evidence-based recommendations for the treatment of noninfectious uveitis in the era of biologics. CLINICAL RELEVANCE: The availability of biologic agents for the treatment of human eye disease has altered practice patterns for the management of noninfectious uveitis. Current guidelines are insufficient to assure optimal use of noncorticosteroid systemic immunomodulatory agents. METHODS: An international expert steering committee comprising 9 uveitis specialists (including both ophthalmologists and rheumatologists) identified clinical questions and, together with 6 bibliographic fellows trained in uveitis, conducted a Preferred Reporting Items for Systematic Reviews and Meta-Analyses protocol systematic review of the literature (English language studies from January 1996 through June 2016; Medline [OVID], the Central Cochrane library, EMBASE, CINAHL, SCOPUS, BIOSIS, and Web of Science)...
January 6, 2018: Ophthalmology
https://www.readbyqxmd.com/read/29304942/conducting-a-discrete-choice-experiment-study-following-recommendations-for-good-research-practices-an-application-for-eliciting-patient-preferences-for-diabetes-treatments
#18
Ellen M Janssen, A Brett Hauber, John F P Bridges
OBJECTIVES: To consolidate and illustrate good research practices in health care to the application and reporting of a study measuring patient preferences for type 2 diabetes mellitus medications, given recent methodological advances in stated-preference methods. METHODS: The International Society for Pharmacoeconomics and Outcomes Research good research practices and other recommendations were used to conduct a discrete-choice experiment. Members of a US online panel with type 2 diabetes mellitus completed a Web-enabled, self-administered survey that elicited choices between treatment pairs with six attributes at three possible levels each...
January 2018: Value in Health: the Journal of the International Society for Pharmacoeconomics and Outcomes Research
https://www.readbyqxmd.com/read/29260508/a-systematic-review-of-the-cost-effectiveness-of-biologics-for-ulcerative-colitis
#19
REVIEW
Ewa Stawowczyk, Paweł Kawalec
BACKGROUND: Ulcerative colitis (UC) is a chronic autoimmune inflammation of the colon. The condition significantly decreases quality of life and generates a substantial economic burden for healthcare payers, patients and the society in which they live. Some patients require chronic pharmacotherapy, and access to novel biologic drugs might be crucial for long-term remission. The analyses of cost-effectiveness for biologic drugs are necessary to assess their efficiency and provide the best available drugs to patients...
December 19, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29260237/-anticoagulation-in-geriatric-patients-with-atrial-fibrillation-with-what-and-for-whom-no-more
#20
REVIEW
P Bahrmann, M Christ
Based on established risk scores, such as the CHA 2 DS 2 -VASc score, the indications for oral anticoagulation are given for patients over 65 years old with atrial fibrillation and even more so for patients over 75 years old. Before beginning anticoagulation a geriatric assessment for evaluation of the cognitive ability, the activities of daily living and the risk of falling should be made because of the known complications of anticoagulation. Geriatric patients with non-valvular atrial fibrillation (AF) are increasingly being treated with non-vitamin K antagonist oral anticoagulants (NOAC) to prevent ischemic stroke...
December 19, 2017: Herz
keyword
keyword
9163
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"